Colin Harvey is one of the co-founders and the current Head of Platform at Hexagon Bio, a biotech devoted to the discovery and development of new medicines from fungal natural products. Dr. Harvey completed his B.Sc. from McGill University in 2005 and undertook a PhD in Chemistry at Stanford University under the mentorship of Prof. Chaitan Khosla studying the engineered biosynthesis of novel macrolide antibiotics. In 2021, he continued his training as a Postdoctoral Fellow with Prof. Ron Davis at the Stanford Genome Technology Center. During his time at the SGTC, Dr. Harvey worked on the application of synthetic biology and genomics to the discovery of novel fungal natural products. This work led directly to the founding of Hexagon Bio by Colin and several of his colleagues in 2017.